摘要
Abstract
Objective To assess the efficacy of interferon-α (IFN-α) and ribavirin in treatment of hepatitis C virus-associated mixed cryoglobulinemia.Methods A thorough literature on interferon-α (IFN-α) and ribavirin in treatment of hepatitis C virus-associated mixed cryoglobulinemia was searched among PubMed,OVID,Springer,CCTR (Cochrane Controlled Trails Register),Wanfang,VIP full text database,et al.A meta analysis was performed on a total of 169 patients involved in 7 articles which met the inclusion criteria.Results Test for heterogeneity showed that the evolution of alanine aminotransferase (ALT) had homogeneity between the pretreatment and the end of treatment (P =0.18;I2 =41％),which allowed to use the fixed effect model analysis.And the evolution of ALT had homogeneity between the pretreatment and the end of follow-up (P =0.14 ;I2 =50％),which allowed to use the fixed effect model analysis.The evolution of cryocrit also had homogeneity between the pretreatment and the end of treatment,so the fixed effect model analysis was applied.Incorporation analysis showed that ALT reduced by an average of 104.2 IU/L (95％ CI 76.25-132.60,P ＜ 0.000 01)from the pretreatment to the end of treatment.And ALT reduced by an average of 40.04 IU/L (95 ％ CI 26.28-53.80,P ＜ 0.000 01)from the pretreatment to the end of follow-up.Cryocrit reduced by an average of 3.17％ (95％ CI 2.21-3.99,P ＜ 0.000 01) from the pretreatment to the end of treatment.Conclusion The clinical evidences available indicate that IFN-α and ribavirin for hepatitis C virus-associated mixed cryoglobulinemia can significantly improve the liver function by reducing serum alanine amino transferase (ALT) levels,and can also reduce the cryocrit.But it needs the multi-centre and large-scale randomized double blind clinical trials to further demonstrate and support the conclusion.关键词
丙型肝炎/混合型冷球蛋白血症/干扰素-α/利巴韦林/meta分析Key words
hepatitis C/ mixed cryoglobulinemia/ interferon-α(IFN-α) / ribavirin/ meta analysis分类
医药卫生
